Dragonfly Therapeutics Adds Leading Lymphoma Specialist to Its Scientific Advisory Board

News provided by

Dragonfly Therapeutics, Inc.

19 Sep, 2016, 08:08 ET

Dr. Ronald Levy to contribute deep expertise on cancer targets and experience in personalized anticancer drug development, as a scientific advisor to the company 

CAMBRIDGE, Mass., Sept. 19, 2016 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), based in Cambridge, Massachusetts, today announced the addition of Stanford University scientist and renowned lymphoma specialist Ronald Levy, to its Scientific Advisory Board.

Dr. Ronald Levy
Dr. Ronald Levy

"Dr. Levy is widely recognized expert in the biology and treatment of lymphoma. He will be an invaluable contributor to Dragonfly's work developing immunotherapies that eliminate cancer," said Dragonfly's co-founder and head of MIT's Koch Institute, Dr. Tyler Jacks. "We are thrilled to have him join us as an experienced advisor and guide."

Ronald Levy is an American medical doctor and scientist at Stanford University. He specializes in lymphoma, including Non-Hodgkin's Lymphoma, Burkitt's Lymphoma and Hodgkin's Disease. His research investigates how the immune system can be harnessed to fight lymphoma. His work has led to the concept that antibodies can be used as personalized anticancer drugs and to the development of an antibody-based drug, Rituxan, that is widely used to treat lymphoma. Levy's work has been recognized with the American Cancer Society's Medal of Honor, the Karnofsky Award from the American Society of Clinical Oncology, and others. He is a member of the National Academy of Sciences and of the Institute of Medicine.

"There is virtually no one in the world who has escaped the devastating experience of a family member or friend, with cancer," said Dr. Levy.  "We are in the midst of a revolution in personalized medicine, including anticancer drugs. New immunotherapies represent one of the greatest opportunities ever seen in modern medicine, and am thrilled to assist the Dragonfly team in their development of novel drugs that fight cancer."

For more information on Dragonfly, email [email protected]. Or, visit www.dragonflytx.com, follow Dragonfly on Facebook https://www.facebook.com/dragonflytherapeutics/) and Twitter @dragonflytx).

About Dragonfly Therapeutics
Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer. 

We are developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system.

Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients.

Media Contact:
Maura McCarthy
Dragonfly Therapeutics
617.780.1660
[email protected]

Photo - http://photos.prnewswire.com/prnh/20160913/407103 
Logo - http://photos.prnewswire.com/prnh/20160719/390962LOGO

SOURCE Dragonfly Therapeutics, Inc.

Related Links

http://www.dragonflytx.com

Also from this source

Dragonfly Therapeutics annonce la présentation des résultats de la phase 1 de l'augmentation de dose du DF1001 TriNKET® lors de la réunion annuelle de l'ASCO 2023

Dragonfly Therapeutics anuncia los resultados del aumento de dosis de DF1001 TriNKET® en ASCO 2023

Explore

More news releases in similar topics

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.